We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
£21 million is being allocated to 64 NHS trusts across England to roll out AI tools to speed up the diagnosis and treatment of lung cancer.
This article presents new 5-year cancer survival estimates by stage and outlines how stage of diagnosis for different cancers affects health outcomes.
Government to take forward UK National Screening Committee recommendation on use of digital images to make it easier to identify cancer and speed up diagnosis.
Population-based statistics on diagnostic intervals for cancer patients for 24 cancer types diagnosed in 2014 and 2015 in England.
Implementation of a series of public awareness campaigns to support the Government’s priority to achieve better cancer outcomes
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
This aims to help GPs in determining which patients would be suitable for direct referral to local services providing the diagnostic tests.
Survival for people diagnosed by cancer type, split by stage at diagnosis. Data based on people diagnosed in England in 2012, 2013 and 2014.
Overview of the UK's cancer research infrastructure and the advantages of investing in the UK's life science sector to develop new treatments.
Cancer survival statistics for adults and children by stage at diagnosis and by different geographical variations.
One-year and 3-year case-mix adjusted percentage of cancers diagnosed at stages 1 and 2, as compared to stages 1 to 4, by Clinical Commissioning Group for 21 cancer groups.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.